Pioneering antigen-agnostic TCR T cell therapies

Get to Know Us

Tcelltech GmbH, a spin-out of the German Cancer Research Center (DKFZ), is focussed on bringing T cell therapies against cancer to patients. We have developed a first-in-class personalized adoptive cell therapy (UNIPACT) to eradicate tumors. The core of UNIPACT is a proprietary discovery pipeline that isolates tumor reactive T cell receptors from each patient and delivers these to autologous T cells using a novel DNA-vector delivery platform called nanoSMAR.


© 2022 Tcelltech GmbH. All rights reserved.